Share on:

Drug Discovery and Development

CCaTS Drug Discovery image

Mayo Clinic's Center for Clinical and Translational Science (CCaTS) offers resources to help investigators through the discovery, development and testing of novel therapeutics. These new drugs may lead to a reduction in symptoms, improved quality of life or possibly a reversal of hard-to-treat diseases. This service is available to investigators at all Mayo Clinic campuses.

CCaTS's Drug Discovery and Development involves collaboration with several external organizations. Through these collaborations, CCaTS fosters academic as well as public-private partnerships in the drug discovery, development and testing process.

These collaborators work with Mayo Clinic to offer drug discovery and development services to investigators:

Sanford-Burnham Medical Research Institute

Mayo Clinic collaborates with Sanford-Burnham to expand and speed the development of new therapeutic drugs aimed at a variety of diseases that have unmet medical needs.

Sanford-Burnham is one of four centers in the country funded by the National Institutes of Health (NIH) to develop vast molecular libraries of compounds to effective drug candidates. It has one of the world's largest libraries of chemical compounds and the ability to perform robotic ultrahigh throughput screening, matching those compounds with biological molecules. (For more information about this collaboration, read "Mayo Clinic plugs into drug discovery" in Discovery's Edge, Mayo's online research magazine.)

The collaboration with Sanford-Burnham is funded by a partnership among the Mayo Clinic Research Committee, CCaTS, Mayo Clinic Center for Individualized Medicine, Mayo Clinic Cancer Center and Mayo Clinic Center for Regenerative Medicine.

Preferred project status

Consider applying to the Sanford-Burnham program if you have identified targets for modulation, if you have (or you can develop) screening assays and if you are interested in identifying small molecule compounds.

Funding

If you apply and are selected to participate in this program, funding is provided to collaborate with Sanford-Burnham scientists to validate and optimize a screening assay. Once this is accomplished, NIH and other sources of funding are sought to perform drug screening and lead compound optimization.

GlaxoSmithKline

Mayo Clinic's partnership with GlaxoSmithKline (GSK) involves discovering new pharmacologically active molecules via high-throughput screening and encoded library technology. This collaboration is through GSK's Discovery Partnerships with Academia program.

It involves collaboration at many levels and includes access to:

  • GSK libraries for small molecule screening
  • GSK assays, medicinal chemistry and formulation resources
  • GSK resources for biologics development, such as peptide or protein synthesis and antibody maturation and humanization

Preferred project status

Consider applying to the GlaxoSmithKline program if you have identified targets and have (or can develop) assays for small molecule screening; if you have compounds that need optimization, testing or formulation; or if you have identified therapeutic peptides, antibodies or vaccine candidates.

Funding

If you apply and are selected to participate in this program, funding is provided through GlaxoSmithKline.

Eli Lilly and Co.

Mayo Clinic and Eli Lilly and Co. have a collaborative agreement involving Eli Lilly's Open Innovation Drug Discovery program. It includes opportunities for chemical compound screening in Eli Lilly's state-of-the-art biological screening assays. This highly collaborative process is enabled by a Web-based application that facilitates efficient transfer of information between Eli Lilly and Mayo Clinic investigators.

Preferred project status

Consider applying to the Eli Lilly program if you have identified a chemical compound for potential screening.

Funding

If you apply and are selected to participate in this program, funding is provided through Eli Lilly.

National Center for Advancing Translational Sciences

The National Center for Advancing Translational Sciences (NCATS) is an NIH center with an open database of clinical compounds available for repurposing. These compounds failed in clinical trials due to efficacy but not safety. Compounds in the database are Phase I ready.

Preferred project status

Consider searching the NCATS compound database if you have identified a target in a signaling pathway associated with a disease indication. You can search the NCATS database by target name and determine if a compound exists to modulate that target. If you find a compound that can modulate your target, you can apply through NCATS for access to the compound and funding to support phase I and phase II testing.

Funding

If you apply and are selected to participate in this program, access to the compound and funding is provided through NCATS.

Nanosyn

Nanosyn is a medicinal chemistry and biological services contract research organization. It offers hit-to-lead expansion, lead optimization, chemical synthesis and other medicinal chemistry services.

Preferred project status

Consider applying to work with Nanosyn if you have a lead compound and are seeking to optimize that lead.

Funding

Nanosyn is a fee-for-service organization. To work with Nanosyn, you need to have funding available to pay for its services. Nanosyn is willing to work with investigators to co-apply for NIH, Small Business Innovation Research, Small Business Technology Transfer and foundation grants to support development work.

Orphagen Pharmaceuticals

Orphagen Pharmaceuticals is a contract research organization that focuses on identifying drug-like small molecules that regulate novel drug targets. It concentrates on the early stages of small molecule drug discovery: screening, hit-to-lead, lead optimization and preclinical development.

Preferred project status

Consider applying to work with Orphagen if you need services related to small molecule drug development.

Funding

Orphagen is a fee-for-service organization. To work with Orphagen, you need to have funding available to pay for its services.

Preclinical drug development services

Mayo Clinic Ventures has developed a network of fee-for-service external research organizations that provide expertise in drug formulation, preclinical toxicology and medicinal chemistry. They also can offer input regarding interactions with the Food and Drug Administration, including guidance on pre-investigational new drug applications and investigational new drug submissions, among other topics.

These resources are available on a project-by-project basis. Contact Mayo Clinic Ventures for additional information.

Preferred project status

Consider contacting Mayo Clinic Ventures for preclinical drug development services if you have identified a lead compound, either small molecule or biologic.

Funding

You need to have funding available to pay for preclinical drug development services.

Other opportunities

Additional funding sources, requests for proposals and other drug development opportunities also are available periodically through CCaTS Drug Discovery and Development.

If you have a project you are interested in pursuing with CCaTS, contact one of the individuals listed in the Contacts section below.

For more information about funding opportunities, refer to the CCaTS Funding Opportunities page.

Contacts

  • Feb 25, 2015
  • ART751686

Investigator profiles

  1. Bram, Richard J., M.D., Ph.D.
    • Pediatric Hematology/Oncology
    • Mayo Clinic, Rochester, Minnesota
  2. McLean, Pamela J., Ph.D.
    • Molecular Neuroscience
    • Mayo Clinic, Jacksonville, Florida
  3. Singh, Vijay P., MBBS
    • Gastroenterology and Hepatology
    • Mayo Clinic, Phoenix/Scottsdale, Arizona